Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) insider Jason B. Shandell sold 6,615 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $20.31, for a total value of $134,350.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ AMPH traded up $0.19 on Friday, hitting $20.20. The company had a trading volume of 112,283 shares, compared to its average volume of 187,317. Amphastar Pharmaceuticals Inc has a 12-month low of $16.07 and a 12-month high of $25.43. The company has a 50 day moving average price of $20.36. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.06 and a quick ratio of 1.35. The firm has a market cap of $961.08 million, a price-to-earnings ratio of 96.19 and a beta of 1.39.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, May 9th. The company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.07. Amphastar Pharmaceuticals had a return on equity of 5.14% and a net margin of 0.74%. The company had revenue of $79.79 million during the quarter, compared to the consensus estimate of $76.21 million. During the same quarter in the prior year, the business earned $0.05 earnings per share. The company’s revenue was up 36.7% compared to the same quarter last year. Equities research analysts predict that Amphastar Pharmaceuticals Inc will post 0.21 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Oregon Public Employees Retirement Fund purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $262,000. Prudential Financial Inc. boosted its position in Amphastar Pharmaceuticals by 8.9% in the 4th quarter. Prudential Financial Inc. now owns 61,995 shares of the company’s stock worth $1,234,000 after purchasing an additional 5,085 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $63,000. California Public Employees Retirement System purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $509,000. Finally, New York State Common Retirement Fund boosted its position in Amphastar Pharmaceuticals by 27.1% in the 4th quarter. New York State Common Retirement Fund now owns 48,186 shares of the company’s stock worth $959,000 after purchasing an additional 10,286 shares in the last quarter. 47.64% of the stock is owned by institutional investors.
AMPH has been the subject of several research analyst reports. TheStreet upgraded Patrick Industries from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. BidaskClub downgraded Zynerba Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 29th. Wells Fargo & Co set a $29.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 6th. Finally, Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Buy” and an average target price of $24.64.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
See Also: Resistance Level
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.